Mirum Pharmaceuticals Inc (MIRM)
44.73
+1.25
(+2.87%)
USD |
NASDAQ |
Nov 22, 16:00
44.73
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Revenue (TTM): 307.03M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 307.03M |
| June 30, 2024 | 264.38M |
| March 31, 2024 | 224.00M |
| December 31, 2023 | 186.37M |
| September 30, 2023 | 144.73M |
| June 30, 2023 | 115.78M |
| Date | Value |
|---|---|
| March 31, 2023 | 95.77M |
| December 31, 2022 | 77.06M |
| September 30, 2022 | 52.29M |
| June 30, 2022 | 38.51M |
| March 31, 2022 | 32.03M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
32.03M
Minimum
Mar 2022
307.03M
Maximum
Sep 2024
139.81M
Average
115.78M
Median
Jun 2023
Revenue (TTM) Benchmarks
| Arcutis Biotherapeutics Inc | 138.71M |
| Cytokinetics Inc | 3.219M |
| Amicus Therapeutics Inc | 493.67M |
| MannKind Corp | 267.20M |
| TG Therapeutics Inc | 264.79M |